Cargando…
Butyricimonas virosa Peritonitis in Peritoneal Dialysis Patient: A Case Report and Review
Butyricimonas virosa is a Gram-negative bacillus, which was first discovered in rat faeces in 2009. To date, only seven human infections have been reported in literature. To our knowledge, this is the first reported case of peritoneal dialysis (PD)-related peritonitis due to B. virosa. A 65-year-old...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743142/ https://www.ncbi.nlm.nih.gov/pubmed/36518359 http://dx.doi.org/10.1159/000525177 |
_version_ | 1784848669733814272 |
---|---|
author | Lau, Siew Yan Bee, Boon Cheak Wong, Hin-Seng Abdul Hameed, Ahneez |
author_facet | Lau, Siew Yan Bee, Boon Cheak Wong, Hin-Seng Abdul Hameed, Ahneez |
author_sort | Lau, Siew Yan |
collection | PubMed |
description | Butyricimonas virosa is a Gram-negative bacillus, which was first discovered in rat faeces in 2009. To date, only seven human infections have been reported in literature. To our knowledge, this is the first reported case of peritoneal dialysis (PD)-related peritonitis due to B. virosa. A 65-year-old Chinese man presented to the hospital with complaints of dizziness and vomiting. On admission, the drained peritoneal dialysate was cloudy. He was empirically treated as a case of PD-related peritonitis with intraperitoneal (IP) cefazolin, ceftazidime, and gentamicin. B. virosa was isolated from peritoneal fluid sample and the antibiotics were changed to IP imipenem and amikacin. Three weeks after completion of the antibiotics, the patient presented again with cloudy peritoneal dialysate and blood stained diarrhoea. IP imipenem and amikacin were recommenced. Multiple peritoneal dialysate samples were sent to the microbiology laboratory, but this time no microorganism was isolated. Colonoscopy examination revealed the presence of extensive rectosigmoidal ulcerations. IP imipenem was replaced with IP piperacillin-tazobactam when the patient developed imipenem-associated neurotoxicity at Day 9 of treatment. The patient recovered fully after completing 3 weeks of IP piperacillin-tazobactam and 2 weeks of IP amikacin. This is the first reported case of PD-related peritonitis due to B. virosa. Susceptibility data for B. virosa are scarce, but a 3-week course of IP piperacillin-tazobactam, imipenem, or meropenem could be potentially useful in treating PD-related peritonitis caused by this organism. |
format | Online Article Text |
id | pubmed-9743142 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-97431422022-12-13 Butyricimonas virosa Peritonitis in Peritoneal Dialysis Patient: A Case Report and Review Lau, Siew Yan Bee, Boon Cheak Wong, Hin-Seng Abdul Hameed, Ahneez Case Rep Nephrol Dial Single Case Butyricimonas virosa is a Gram-negative bacillus, which was first discovered in rat faeces in 2009. To date, only seven human infections have been reported in literature. To our knowledge, this is the first reported case of peritoneal dialysis (PD)-related peritonitis due to B. virosa. A 65-year-old Chinese man presented to the hospital with complaints of dizziness and vomiting. On admission, the drained peritoneal dialysate was cloudy. He was empirically treated as a case of PD-related peritonitis with intraperitoneal (IP) cefazolin, ceftazidime, and gentamicin. B. virosa was isolated from peritoneal fluid sample and the antibiotics were changed to IP imipenem and amikacin. Three weeks after completion of the antibiotics, the patient presented again with cloudy peritoneal dialysate and blood stained diarrhoea. IP imipenem and amikacin were recommenced. Multiple peritoneal dialysate samples were sent to the microbiology laboratory, but this time no microorganism was isolated. Colonoscopy examination revealed the presence of extensive rectosigmoidal ulcerations. IP imipenem was replaced with IP piperacillin-tazobactam when the patient developed imipenem-associated neurotoxicity at Day 9 of treatment. The patient recovered fully after completing 3 weeks of IP piperacillin-tazobactam and 2 weeks of IP amikacin. This is the first reported case of PD-related peritonitis due to B. virosa. Susceptibility data for B. virosa are scarce, but a 3-week course of IP piperacillin-tazobactam, imipenem, or meropenem could be potentially useful in treating PD-related peritonitis caused by this organism. S. Karger AG 2022-09-26 /pmc/articles/PMC9743142/ /pubmed/36518359 http://dx.doi.org/10.1159/000525177 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Single Case Lau, Siew Yan Bee, Boon Cheak Wong, Hin-Seng Abdul Hameed, Ahneez Butyricimonas virosa Peritonitis in Peritoneal Dialysis Patient: A Case Report and Review |
title | Butyricimonas virosa Peritonitis in Peritoneal Dialysis Patient: A Case Report and Review |
title_full | Butyricimonas virosa Peritonitis in Peritoneal Dialysis Patient: A Case Report and Review |
title_fullStr | Butyricimonas virosa Peritonitis in Peritoneal Dialysis Patient: A Case Report and Review |
title_full_unstemmed | Butyricimonas virosa Peritonitis in Peritoneal Dialysis Patient: A Case Report and Review |
title_short | Butyricimonas virosa Peritonitis in Peritoneal Dialysis Patient: A Case Report and Review |
title_sort | butyricimonas virosa peritonitis in peritoneal dialysis patient: a case report and review |
topic | Single Case |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743142/ https://www.ncbi.nlm.nih.gov/pubmed/36518359 http://dx.doi.org/10.1159/000525177 |
work_keys_str_mv | AT lausiewyan butyricimonasvirosaperitonitisinperitonealdialysispatientacasereportandreview AT beebooncheak butyricimonasvirosaperitonitisinperitonealdialysispatientacasereportandreview AT wonghinseng butyricimonasvirosaperitonitisinperitonealdialysispatientacasereportandreview AT abdulhameedahneez butyricimonasvirosaperitonitisinperitonealdialysispatientacasereportandreview |